logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2022
Geron Corporation
Top-line results from phase 3 Clinical Trial of imetelstat (IMerge)
Myelodysplastic Syndromes (MDS)
2H 2022
Selecta Biosciences Inc.
Topline data from phase III clinical trial of SEL-212 (DISSOLVE I)
Chronic refractory gout
2H 2022
Selecta Biosciences Inc.
Topline data from phase III clinical trial of SEL-212(DISSOLVE II)
Chronic refractory gout
2H 2022
Harmony Biosciences Holdings, Inc
Topline results from phase II clinical trial of WAKIX
Myotonic dystrophy in adults
Q3 2022
ABEONA THERAPEUTICS INC.
Topline results from Phase 3 trial of EB-101 (VIITAL)
Recessive dystrophic epidermolysis bullosa (RDEB)
Q3 2022
Allena Pharmaceuticals, Inc.
Topline data from phase III program of Reloxaliase (URIROX-2)
Enteric hyperoxaluria
2H 2022
Annexon, Inc.
Initial data from Phase 2 trial of ANX005
Warm autoimmune hemolytic anemia (wAIHA)
2H 2022
Oramed Pharmaceuticals Inc.
ORMP, ORMP.OB
Topline results from phase II trial of oral insulin capsule ORMD-0801
Non-alcoholic steatohepatitis (NASH)
2H 2022
Prometheus Biosciences, Inc
Data from Phase 1b clinical trial of PRA023
Moderate-to-severe Crohn's disease (CD)
2H 2022
Prometheus Biosciences, Inc
Data from Phase 2 randomized placebo-controlled clinical trial of PRA023
Moderate-to-severe ulcerative colitis
2H 2022
Aptinyx Inc
Data from phase II exploratory study of NYX-458 study
Patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies
2H 2022
Verona Pharma plc
Top-line data from phase III trial of Ensifentrine (ENHANCE-1)
Chronic obstructive pulmonary disease (COPD)
2H 2022
Cerevel Therapeutics Holdings Inc.
Data from phase II proof-of-concept trial with Darigabat (REALIZE)
Focal epilepsy
Q3 2022
Caladrius Biosciences, Inc.
Top line data from phase IIb trial of CLBS16 in the U.S.(FREEDOM)
Coronary microvascular dysfunction
2H 2022
IVERIC bio, Inc.
Topline data from pivotal clinical trial of Zimura( GATHER2 )
Geographic atrophy (GA) secondary to age-related macular degeneration
2H 2022
ANAVEX LIFE SCIENCES CORP.
Top-line data from pivotal Phase 2b/3 clinical trial of ANAVEX®2-73-AD-004
Alzheimer's Disease (AD)
2H 2022
RenovoRx, Inc.
Interim data readout from phase III trial of RenovoGem (TIGeR-PaC)
Pancreatic cancer
Q3 2022
Addex Therapeutics Ltd
Data from phase II clinical study of ADX71149
Epilepsy
2H 2022
Chemomab Therapeutics Ltd.
Data from phase IIa trial of CM-101 (SPRING)
Primary Sclerosing Cholangitis
Q3 2022
ANAPTYSBIO INC
Top-line data from phase II trial of Imsidolimab (HARP)
Hidradenitis suppurativa
2H 2022
Harmony Biosciences Holdings, Inc
Topline results from phase II trial of Wakix
Myotonic dystrophy
2H 2022
SCYNEXIS, Inc.
Top line results from phase II trial of oral Ibrexafungerp with Voriconazole (SCYNERGIA)
Invasive pulmonary aspergillosis
Q3 2022
Immunogen Inc
Top-line data from Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy( MIRASOL )
Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
2H 2022
Context Therapeutics Inc.
Preliminary data from phase 2 trial of ONA-XR
2L/3L metastatic breast cancer
2H 2022
Context Therapeutics Inc.
Preliminary data from two phase 0 biomarker pharmacodynamic trials of ONA-XR
Breast cancer